Clinical trial

Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission

NCT00115648

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Nevirapine Normalized identity: nevirapineView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention AZT Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention NVP and AZT Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention NVP Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention NVP+AZT Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-04-01

PhasePHASE3

Conditions

HIV Infectionsunresolved

Interventions

NevirapineDRUG · verified · RxNorm: nevirapine

AZTDRUG

NVP and AZTDRUG

NVPDRUG

NVP+AZTDRUG

Sponsors & collaborators

Johns Hopkins Bloomberg School of Public Healthlead sponsor

Centers for Disease Control and Preventioncollaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00115648 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.